Phase 2 N=452 A Safety and Efficacy Study of Tralokinumab in Adults With Asthma
Asthma
Primary: Annual Asthma Exacerbation Rate (AER) — 0.90; 0.91; 0.97 AER events/person-year — p=0.709
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=126 Polyp Detection With the EndoRings™: A Randomized Tandem Colonoscopy Study
Colon Cancer
Primary: Adenoma and Polyp Miss Rate — 48.3; 10.4; 52.8; 9.1 percentage of :Adenomas/Polyp missed
Phase 3 N=763 Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis
Dermatitis, Atopic
Primary: Percentage of Participants Who Achieved Treatment Success Based on Investigator's Static Global Assessment (ISGA) at Day 29 — 32.8; 25.4 percentage of participants…
Phase 4 N=43 BK Treatment Study
BK Viremia
Primary: Percent Change From Baseline in BK Virus Copies at 3 Months — 70.3; 69.1 Percent change of BK virus copies
N/A N=40 Transcutaneous pO2, Transcutaneous pCO2 and Central Venous SO2 Variations to Define Fluid Responsiveness
Hypotension · Shock · Fluid Challenge
Primary: Fluid Responsiveness — 18 Participants
Phase 4 N=106 Evaluation of Modified Treatment Regimens for Treatment of Heavy Menstrual Bleeding Using the HerOption® System
Menorrhagia
Primary: Success (Reduction in Menstruation to Normal Levels) — 59 Participants — p=.271
N/A N=60 In Vitro Pharmacodynamic Effects of Cangrelor in Ticagrelor Treated Patients
Coronary Artery Disease
Primary: Platelet Reactivity Index (PRI) Determined by Whole Blood Vasodilator-stimulated Phosphoprotein (VASP) — 30; 30; 18; 17 %PRI
Phase 3 N=1,482 Efficacy and Safety Study of SCH 900237/MK-8237 in Children and Adults With House Dust Mite-Induced Allergic Rhinitis/Rhinoconjunctivitis (P05607)
Rhinitis, Allergic, Perennial · Rhinitis, Allergic, Nonseasonal
Primary: Average Total Combined Rhinitis Score (TCRS) During Last 8 Weeks of Treatment — 4.67; 5.49 Score on a Scale — p=<0.001
N/A N=128 Time and Motion Related to PICC Insertion Process and Catheter Tip Confirmation
Indication for PICC Placement
Primary: Time From Initiation of Procedure (Opening of PICC Kit) to Catheter Tip Confirmation (Release for IV Therapy). — 176.32; 33.93 minutes
Phase 2 N=21 Randomized, Controlled, Open-label, Multicenter, Safety and Efficacy Study of rhHNS Administration Via an IDDD in Pediatric Patients With Early Stage MPS IIIA Disease
Sanfilippo Syndrome
Primary: Number of Participants With Overall Response Using Bayley Scales of Infant Development Assessment Third Edition (BSID-III) — 0; 2; 1 participants — p=0.4615
N/A N=161 Increasing Use of Mental Health Services
Major Depression
Primary: The Primary Outcome is Engagement Defined as at Least One Visit With a Mental Health Provider Who Can Offer Treatment of Depression. — 74.1; 56.3 percentage of…
N/A N=45 A Study to Investigate the Antimicrobial Activity of 2 Test Toothpastes
Dental Plaque
Primary: Area Under the Curve for Glycolysis (AUCgly(0-90)) of Test Zinc-IPMP and Non-SLS Negative Control — 42.64; 2.46 plaque incubation pH*min — p=<0.0001
Phase 2 N=14 Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Response Rates After Amrubicin + Lenalidomide + Dexamethasone, Per International Myeloma Working Group Uniform Response Criteria — 0; 7.6; 7.6; 15.4 percentage of…
N/A N=99 Ketamine/Placebo Family History Positive Study
Alcoholism
Primary: Biphasic Alcohol Effects Scale (BAES) - Subscale Sedation — 0.63; 0.96; 0.71; 1.25 units on a scale
Phase 3 N=282 Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection
Helicobacter Pylori Infection
Primary: Sensitivity is Described as the Accuracy of the Breath Test in Detecting H.Pylori Infection Compared to Biopsy — 98.32; 98.53 Percent positive agreement